News & Analysis as of

Research and Development Gilead Sciences

Sunstein LLP

“We’re Here to Help.” Government’s Ideal Role in Sparking Medical Advances?

Sunstein LLP on

Last month the United States Government Accountability Office (GAO) was asked to review federal contributions to the R&D of the drug remdesivir and determine government agencies' patent rights to the drug. The GAO determined...more

Mitratech Holdings, Inc

Gilead Sciences: A Lesson in How Legal Ops Empowers Business Continuity

At our Virtual Summit, Continuity Beyond Coronavirus, the keynote session starting everything off will feature a Legal Ops leader who’s seen his company skyrocket to national – even global – prominence over the last several...more

Troutman Pepper

NIH May Own Gilead's Blockbuster Hepatitis Drug Due to Misstep

Troutman Pepper on

Every year, the National Institutes of Health (NIH) spends billions of federal dollars on research and development of new drugs and therapies for treating and preventing serious illnesses....more

Foley & Lardner LLP

Are Drug Prices Really Too High?

Foley & Lardner LLP on

Those working in the pharmaceutical space are used to hearing complaints about the high costs of drugs, and patents often are blamed for allowing pharmaceutical companies to charge “too much” for their products. But are drug...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide